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Abstract
Background: Several randomized controlled trials have shown that adjuvant immunotherapy with autologous
cytokine-induced killer (CIK) cells prolongs recurrence-free survival (RFS) after curative treatment for hepatocellular
carcinoma (HCC). We investigated the efficacy of adjuvant immunotherapy with activated CIK cells in real-world
clinical practice.
Methods: A total of 59 patients who had undergone curative surgical resection or radiofrequency ablation for
stage I or II HCC, and subsequently received adjuvant CIK cell immunotherapy at two large-volume centers in
Korea were retrospectively included. Propensity score matching with a 1:1 ratio was conducted to avoid possible
bias, and 59 pairs of matched control subjects were also generated. The primary endpoint was RFS and the secondary
endpoints were overall survival and safety.
Results: The median follow-up duration was 28.0 months (interquartile range, 22.9–42.3 months). In a univariable
analysis, the immunotherapy group showed significantly longer RFS than the control group (hazard ratio [HR], 0.42;
95% CI, 0.22–0.80; log-rank P = 0.006). The median RFS in the control group was 29.8 months, and the immunotherapy
group did not reach a median RFS. A multivariable Cox proportional hazard analysis showed that immunotherapy was
an independent predictor for HCC recurrence (adjusted HR, 0.38; 95% CI, 0.20–0.73; P = 0.004). The overall incidence of
adverse events in the immunotherapy group was 16/59 (27.1%) and no patient experienced a grade 3 or 4 adverse
event.
Conclusions: The adjuvant immunotherapy with autologous CIK cells after curative treatment safely prolonged the
RFS of HCC patients in a real-world setting.
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Background
Hepatocellular carcinoma (HCC) is an aggressive cancer
that most often occurs in patients with chronic liver dis-
ease and cirrhosis. The use of active surveillance pro-
grams for these high-risk patients can detect HCC at an
early stage and improve survival [1–3]. Surgical liver re-
section and radiofrequency ablation (RFA) are the most
frequently used curative treatment options for early
stage HCC patients with preserved liver function [4, 5].
However, approximately 70% of HCC patients who
undergo surgical resection or RFA will experience recur-
rence within 5 years [6]. Together with hepatic decom-
pensation, the recurrence of HCC are the major causes
of mortality in these patients [7]. Therefore, the effective
adjuvant therapies that can be applied after curative
treatments to reduce recurrence are urgently needed.
Cytokine-induced killer (CIK) cells are a class of non-
major histocompatibility complex (MHC)-restricted T
lymphocytes that comprise CD3+/CD56+ cells, CD3
+/CD56- cytotoxic T cells, and CD3+/CD56- natural
killer (NK) cells [8]. They are generated ex vivo by incu-
bation of human mononuclear cells with stimulative
anti-CD3 antibody and interleukin (IL)-2 [9]. Because
CIK cells can recognize MHC-lost or -downregulated
malignant cells, which escape immune surveillance, ren-
dered CIK cells can be a therapeutic option for tumors
[10]. Several randomized controlled trials (RCTs) have
shown that adjuvant CIK cell immunotherapy given after
curative treatment for HCC reduces the rate of HCC re-
currence with minimal side effects [11–14]. We previ-
ously reported an RCT that used a commercialized
autologous CIK cell-based immunotherapeutic agent
(ImmunCell-LC®; Green Cross Cell Corp, Seoul, Korea)
manufactured in a Good Medical Practice (GMP)-certi-
fied facility. In that study, adjuvant CIK cell immuno-
therapy prolonged both recurrence-free survival (RFS)
and overall survival (OS) [12]. Up until now,
ImmunCell-LC® has been the only CIK cell agent com-
mercially available.
This study was designed to assess whether the previ-
ously reported efficacy and safety of using ImmunCell-LC®
as an adjuvant therapy after curative HCC treatment
could be reproduced in a real-world clinical setting.
Methods
Patients
Patients who underwent a potentially curative treatment
(surgical resection or RFA) for HCC were eligible for
this study. The patients were assigned to two groups:
those who had received adjuvant immunotherapy with a
CIK cell agent (the immunotherapy group) and those
who had not received any adjuvant treatment (the control
group). HCC was diagnosed by histologic examination or
radiologic imaging studies, according to guidelines of the
American Association for the Study of Liver Diseases [15].
The study inclusion criteria were as follows: 1) stage I or
II HCC based on radiologic findings described in the 6th
edition of the American Joint Committee on Cancer
(AJCC) Staging Manual; 2) Child-Pugh class A liver func-
tion; 3) an Eastern Cooperative Oncology Group perform-
ance status score ≤ 1. The study exclusion criteria were as
follows: 1) Previous history of HCC treatment within 2
years prior to curative treatment; 2) less than 3months of
CIK infusion for patients in the immunotherapy group; 3)
having received other adjuvant therapies for patients in
the control group. Any patient who received CIK cell im-
munotherapy in a previous clinical trial was not included
in this study.
Study design and treatment protocol
The study was performed in accordance with the Declar-
ation of Helsinki and approved by institutional review
board of Seoul National University Hospital (SNUH,
Seoul, Korea) and Samsung Medical Center (SMC, Seoul,
Korea). This phase 4 clinical study was a multicenter,
open-labeled trial conducted at two large-volume tertiary
hospitals in Korea: SNUH and SMC. All enrolled patients
underwent surgical resection or RFA as a curative treat-
ment for HCC and had a medically-confirmed complete
response. Patients in the immunotherapy group were en-
rolled from two centers (SNUH and SMC). As the two
centers showed comparable treatment outcomes (RFS and
OS) after curative treatment for HCC in our recent study
(unpublished data), we enrolled patients in the control
group from one center (SNUH).
For preparation of the individualized CIK cell agent,
150 mL of peripheral blood was collected from each
patient in the immunotherapy group 2–3 weeks before
initiating immunotherapy. Peripheral blood mono-
nuclear cells (PBMCs) were extracted by leukapheresis
and then expanded for 12–21 days with cytokines (IL-2
and anti-CD3 monoclonal antibody) according to our
previously reported protocol [12]. A 200 mL aliquot of
the prepared CIK cell agent was injected intravenously
into patients in the immunotherapy group over a period
of 60 min; after which, the patients were observed for at
least 30 min to identify any immediate side effects. The
CIK cell agent was scheduled to be injected 16 times
over a period of 59 weeks (4 treatments every 1 week,
4 treatments every 2 weeks, 4 treatments every 4
weeks, and 4 treatments every 8 weeks). Treatment
was discontinued when HCC recurrence was detected.
Endpoints and treatment evaluation
The primary endpoint of this study was RFS, which was
calculated from the date of curative treatment to the
first HCC recurrence or death from any cause. The sec-
ondary endpoints were OS and safety. OS was calculated
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from the date of curative treatment to death from any
cause. The date used for all-cause mortality was obtained
from patient medical records and from the Korean Minis-
try of Government Administration and Home Affairs. The
data cut-off date was March 31, 2019. To assess the safety
of the CIK cell agent, AEs (adverse events) were investi-
gated from the date of initiating adjuvant CIK cell im-
munotherapy until the end of the study or patient drop-
out in the immunotherapy group. AEs were graded ac-
cording to National Cancer Institute Common Termin-
ology Criteria for Adverse Events, Version 3.0.
The baseline laboratory findings for patients in both
groups were collected between 1 and 3months after
curative treatment, because acute liver function abnor-
malities may occur immediately after treatment. Labora-
tory results for patients in the immunotherapy group
were collected prior to starting the adjuvant treatment
with the CIK cell agents. Treatment evaluations were
performed by dynamic computed tomography or mag-
netic resonance imaging every 3 months for the first 24
months and every 3–6 months thereafter in both groups.
Statistical analysis
A 1:1 ratio propensity score (PS) matching analysis was
performed to reduce selection bias due to differences in
baseline characteristics between the two groups. A PS
was calculated for each patient based on a multivariable
logistic regression model. The variables in the model in-
cluded age, sex, treatment modality, HCC stage, number
of HCCs, size of the HCC, underlying liver disease, cir-
rhosis, prothrombin time, platelet count, lymphocyte-to-
monocyte ratio, serum levels of alpha-fetoprotein (AFP),
protein induced by vitamin K absence (PIVKA)-II, aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), total bilirubin, and albumin. The nearest neigh-
bor method was used in match selection. That method,
matches a patients with another patient whose PS is
closest to their own [16]. Standardized mean differences
were calculated to ensure that the variables in the two
groups were well-balanced.
Data are expressed as a median value (IQR) or n (%).
Comparisons between patients in the two groups were
assessed using Mann-Whitney’s U-test for continuous
data and the chi-square or Fisher’s exact test for categor-
ical data. Survival curves (RFS and OS) were calculated
by the Kaplan-Meier method, and a log-rank test or a
Firth’s method were used for group comparisons. Crude
HRs were calculated using the Cox proportional hazard
model. A Forest plot of subgroup analyses was con-
structed to compare the ongoing effect of immunother-
apy on the RFS of patients in the immunotherapy group
with those of patients in the control group. Using statisti-
cally significant variables in a univariable analysis, multi-
variable Cox proportional hazard analysis was performed
to identify factors associated with RFS. P-values < 0.05 were
considered statistically significant. R package MatchIt, Ver-
sion 3.4.4 (R Foundation for Statistical Computing, Vienna,
Austria) was used for the PS matching. All other statistical
analyses were performed using IBM SPSS Statistics for Win-
dows, Version 23.0 (IBM, Corp., Armonk, NY, USA).
Results
Patients
From February 2014 to December 2017, a total of 78
HCC patients underwent curative surgical resection or
RFA and then received the CIK cell agents at two large-
volume medical centers in Korea. A total of 59 patients
satisfied the study inclusion criteria and were assigned
to the immunotherapy group: 24 at SNUH and 35 at
SMC. During the same period, a total of 1884 HCC pa-
tients underwent curative treatments with no adjuvant
therapy at a single medical center (SNUH). We ran-
domly selected 236 of those patients, which was 4-fold
the number of patients in the immunotherapy group, by
using a PS matching model consisting of two variables
(age and sex). Among those selected patients, 158 satis-
fied the study inclusion criteria. We then performed a 1:
1 PS matching for those 158 patients and 59 patients in
the immunotherapy group. Finally, 59 pairs of patients
were selected for inclusion in the immunotherapy group
and control group (Fig. 1). Among 59 patients in the im-
munotherapy group, 5 had previous history of treat-
ments with a median time from the prior treatment of
46 months (range, 24–55 months). Whereas, all patients
in the control group did not have a previous history of
treatment. The median follow-up durations for patients
in the immunotherapy group and control group were
31.5months (interquartile range [IQR], 23.1–47.0months)
and 26.9months (IQR, 22.8–40.7months), respectively.
There were several differences in baseline characteris-
tics between the immunotherapy group and control
group prior to the PS matching. The HCC stage (P =
0.018) and prevalence of cirrhosis (P < 0.001) were sig-
nificantly higher in the immunotherapy group, and the
serum levels of AST, albumin, and total bilirubin were
significantly different in the two groups (all P < 0.05).
After PS matching, all the variables of baseline charac-
teristics were comparable between the two groups, with
a ≤ 0.25 standardized mean difference (Table 1).
Recurrence-free survival
In a univariable analysis, the immunotherapy group
showed a significantly longer RFS than the control group
(hazard ratio [HR], 0.42; 95% confidence interval [CI],
0.22–0.80; log-rank P = 0.006) (Fig. 2a). A median RFS
was not reached in the immunotherapy group, and that
in the control group was 29.8 months. There was a sta-
tistically significant difference in RFS between the two
Yoon et al. BMC Cancer          (2019) 19:523 Page 3 of 10
groups. Fifteen of the 59 patients (25.4%) in the im-
munotherapy group and 27 of the 59 patients (45.8%) in
the control group experienced tumor recurrence or
death during the study period. The crude HR for RFS in
the immunotherapy group vs. the control group was
0.42 (95% CI, 0.22–0.80, P = 0.008). A Forest plot of the
crude HRs with a 95% CI for RFS according to sub-
group showed that the immunotherapy group had a
longer RFS than the control group in all the sub-
groups, except etiology of HCC which was not statis-
tically significant (Fig. 3).
In a univariable Cox proportional hazard analysis, RFS
was significantly associated with immunotherapy, size of
the HCC, lymphocyte to monocyte ratio, serum levels of
AFP, AST, and albumin. (all P < 0.05). In a multivariable
analysis with a stepwise selection, immunotherapy was
an independent negative risk factor for tumor recurrence
or death (adjusted HR, 0.38; 95% CI, 0.20–0.73, P =
0.004) along with the size of the HCC (Table 2). When
we analyzed after excluding the 5 treatment-experienced
patients, the adjusted HR of CIK cell immunotherapy
was 0.38 (95% CI, 0.20–0.74; P = 0.005), which was com-
parable to that of the whole study population. We also
performed additional analysis only in patients enrolled at
one center (SNUH; 24 patients in the immunotherapy
group vs. 59 patients in the control group) after
excluding the 35 patients enrolled at SMC, and the ad-
justed HR (0.31; 95% CI, 0.11–0.87; P = 0.03) of the ana-
lysis was maintained in comparison with that of the
whole study population.
Among 42 patients (15 in the immunotherapy group
and 27 in the control group) with tumor recurrence, pa-
tients received additional treatment with various modal-
ities including transarterial chemoembolization, RFA,
surgical resection, liver transplantation, sorafenib and
external radiation therapy (Additional file 1).
Overall survival
Until the data cut-off date, 5 death had occurred in the
entire study population; 1 patient died in the immuno-
therapy group and 4 patient died in the control group.
The 1 patient in the immunotherapy group died of re-
current HCC. The patients in the control group died of
recurrent HCC (3 patients) or new primary lung cancer
(1 patient). There was no statistically significant differ-
ence in OS between the two groups (P = 0.17 as deter-
mined by Firth’s method) (Fig. 2b).
Safety
AEs occurred in 16 of the 59 (27.1%) patients in the im-
munotherapy group, and all the AEs were of grade 1 or
2 in severity. Fatigue (6.8%) was the most frequently
Fig. 1 CONSORT Diagram. SNUH, Seoul National University Hospital; SMC, Samsung Medical Center; HCC, hepatocellular carcinoma; RFA,
radiofrequency ablation
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reported AE, followed by pyrexia (5.1%) (Table 3). All
the AEs were self-limiting and improved with conserva-
tive management. No patient delayed or stopped their
immunotherapy due to an AE. No infectious complica-
tions or allergic reactions were observed in patients in
the immunotherapy group.
Discussion
The question addressed by the present study was
whether the previously reported efficacy and safety of
administering a CIK cell agent as adjuvant therapy after
curative HCC treatment could be reproduced in real-
world clinical practice. The main finding of the study
was that the adjuvant CIK cell agent prolonged RFS with
minimal side effects in HCC patients who had under-
gone curative treatment. Although the efficacy of the ad-
juvant CIK cell agent has already been demonstrated in
the previous RCT [12], the data in real-world setting has
not been evaluated yet. The participants in RCT, who
are enrolled in a clear set of inclusion and exclusion cri-
teria may not represent real-world population, which
may lead to a bias [17]. Therefore, it is important to val-
idate the positive results of CIK cell immunotherapy in
real-world clinical practice. Moreover, CIK cell immuno-
therapy is not incorporated into the recent clinical
guidelines due to lack of real-world evidence [18, 19].
Table 1 Baseline characteristics of the immunotherapy group and control group before and after propensity score matching










Male sex, N (%) 45 (76.3%) 125 (79.1%) 0.79 45 (76.3%) 46 (78.0%) 1.00 0.040
Age, yrs 57.0 (48.5–62.0) 59.0 (52.0–65.0) 0.28 57.0 (48.5–62.0) 59.0 (52.0–65.0) 0.30 0.158
Treatment modality 1.00 0.37 0.224
RFA 10 (16.9%) 28 (17.7%) 10 (16.9%) 15 (25.4%)
Surgical resection 49 (83.1%) 130 (82.3%) 49 (83.1%) 44 (74.6%)
HCC stage, N (%) 0.02 0.46 0.170
Stage I 25 (42.4%) 97 (61.4%) 25 (42.4%) 30 (50.8%)
Stage II 34 (57.6%) 61 (38.6%) 34 (57.6%) 29 (49.2%)
Number of HCC, N (%) 0.64 1.00 < 0.001
< 3 57 (96.6%) 156 (98.7%) 57 (96.6%) 57 (96.6%)
≥ 3 2 (3.4%) 2 (1.3%) 2 (3.4%) 2 (3.4%)
Size of HCC, cm 2.9 (2.1–3.9) 2.5 (1.7–3.5) 0.07 2.9 (2.1–3.9) 2.3 (1.9–3.6) 0.23 0.115
Cause of liver disease, N (%) 0.76 1.00 < 0.001
HBV infection 53 (89.8%) 136 (86.1%) 53 (89.8%) 53 (89.8%)
HCV infection 2 (3.4%) 8 (5.1%) 2 (3.4%) 2 (3.4%)
Others 4 (6.8%) 14 (8.9%) 4 (6.8%) 4 (6.8%)
Cirrhosis, N (%) 35 (59.3%) 48 (30.4%) < 0.001 35 (59.3%) 31 (52.5%) 0.58 0.137
α-fetoprotein level, ng/mL 3.8 (2.6–6.2) 3.6 (2.5–7.1) 0.56 3.8 (2.6–6.2) 4.1 (2.7–8.5) 0.67 0.091
PIVKA-II, mAU/mL 20.0 (16.0–23.0) 19.0 (16.0–26.0) 0.52 20.0 (16.0–23.0) 20.0 (15.0–25.5) 0.58 0.102
Aspartate aminotransferase level, IU/L 31.0 (26.0–40.0) 26.0 (22.0–34.0) 0.005 31.0 (26.0–40.0) 29.0 (24.0–37.5) 0.37 0.161
Alanine aminotransferase level, IU/L 30.0 (17.5–38.0) 22.5 (17.0–33.0) 0.12 30.0 (17.5–38.0) 22.0 (18.5–33.0) 0.29 0.206
Alkaline phosphatase level, IU/L 78.0 (65.5–95.0) 85.0 (70.0–101.0) 0.16 78.0 (65.5–95.0) 87.0 (73.0–103.0) 0.06 –
Albumin level, g/dL 4.2 (4.0–4.5) 4.1 (3.8–4.3) 0.02 4.2 (4.0–4.5) 4.2 (3.8–4.5) 0.70 0.126
Total bilirubin level, mg/dL 0.6 (0.5–0.8) 0.7 (0.6–0.9) 0.01 0.6 (0.5–0.8) 0.7 (0.6–0.9) 0.06 0.245
Prothrombin time, INR 1.1 (1.0–1.1) 1.1 (1.0–1.2) 0.39 1.1 (1.0–1.1) 1.1 (1.0–1.2) 0.72 0.051
Creatinine level, mg/dL 0.9 (0.8–1.0) 0.8 (0.7–0.9) 0.12 0.9 (0.8–1.0) 0.8 (0.7–0.9) 0.08 –
Platelet, ×103/mm3 165.0 (123.0–221.0) 184.5 (136.0–233.0) 0.17 165.0 (123.0–221.0) 158.0 (130.5–200.0) 0.72 0.069
Lymphocyte to monocyte ratio 4.0 (3.0–5.2) 4.4 (3.6–5.7) 0.09 4.4 (3.6–5.7) 4.2 (2.8–5.4) 0.33 0.005
Data are expressed as n (%), median (interquartile range)
RFA radiofrequency ablation, HCC hepatocellular carcinoma, HBV hepatitis B virus, HCV hepatitis C virus, PIVKA-II protein induced by vitamin K absence-II, INR
international normalized ratio
aA standardized mean difference (d) of < 0.1 indicated very small differences; 0.1–0.3, small differences; 0.3–0.5, moderate differences; > 0.5, considerable differences
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Our study provides real-world evidence that the efficacy
of adjuvant CIK cell immunotherapy in RCT was main-
tained in real-world clinical practice.
CIK cells are non-MHC-restricted T lymphocytes that,
can be expanded ex vivo from a patients’ PBMCs, fol-
lowing stimulation with anti-CD3 antibody and IL-2,
and can exhibit anti-tumor effects in vivo [8–10]. CIK
cells can display not only a T lymphocyte-like phenotype
but also an NK cell-like phenotype [20]. Thus, CIK cells
can exert the natural cytotoxic function of NK cells, and
recognize tumor cells even in the absence of surface an-
tigens [21]. Tumor cells can escape immune surveillance
in various ways, and a loss of antigenicity is one key
mechanism of escape [22]. MHC is the major tissue-
antigen that allows the immune system to recognize
tumor cells, and the loss of MHC causes immune
escape. However, CIK cells can recognize tumor cells
and kill them without a prior exposure or priming with-
out MHC restriction. Due to these unique anti-tumor ef-
fects, CIK cells have been widely studied as a treatment
for various cancers, including HCC [23, 24].
Immunotherapy provided with CIK cells is reported to
be more effective when applied a low tumor burden
stage and in an adjuvant setting [25]. Therefore, we
planned to administer the adjuvant CIK cell immuno-
therapy only to patients with early stage HCC. In this
study, the schedule for CIK cell administration and the
use of the commercialized CIK cell agent were the same
as those described in the RCT that we previously reported
[12]. Several previous RCTs [11–14] and retrospective
studies [26, 27] consistently reported that adjuvant CIK
cell immunotherapy prolongs RFS and/or OS when
Fig. 2 Kaplan-Meier estimates of recurrence-free survival (a) and overall survival (b). HR, hazard ratio; CI, confidence interval
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administered after curative treatment for HCC. However,
the methods used to select the HCC patients, the schedule
for CIK cell administration, and the methods used to pre-
pare CIK cells differed in each study. Some studies en-
rolled HCC patients with more advanced stage and failed
to show a beneficial effect of CIK cell immunotherapy on
OS [11, 13, 14]. The optimal schedule for CIK cell admin-
istration has also been controversial; however, it was re-
ported that the maximum beneficial effect on OS was
achieved when more than 8 cycles of CIK cell administra-
tion were performed [27]. In most of the previous studies,
the investigators produced the CIK cells using their own
cultivation techniques. In contrast, we used commercial-
ized CIK cell agents that had been manufactured in a
GMP-certified facility that had standard operating
procedures and strict quality control standards. We
believe that administering more than 8 cycles of the
commercialized CIK cell agent to early stage HCC pa-
tients in an adjuvant setting may improve the efficacy
of CIK cell immunotherapy.
The adjusted HR for the RFS produced by CIK cell im-
munotherapy in our study was 0.38, which was lower
than that of previously reported studies (HR of 0.59–
0.67) [11–13]. Previous RCTs showed that CIK cell im-
munotherapy was more effective at reducing the rate of
early recurrence (within the first 24 months) than late
recurrence (beyond 24 months) [11–14]. Moreover, the
CIK cell immunotherapy was more effective when ad-
ministered to patients with a low tumor burden [25].
The present study had a relatively short follow-up dur-
ation (median = 28.0 months) and included only stage I
and stage II patients. Therefore, the CIK cell immuno-
therapy used in this study was more effective at prolong-
ing RFS than the CIK cell immunotherapies used in
previous studies. However, we did not show that the
CIK immunotherapy prolonged the OS of the HCC pa-
tients. Because this study had a short follow-up duration,
there was only 1 patient death in the immunotherapy
group and 4 patients death in the control group. A lon-
ger follow-up duration is needed to demonstrate any
survival benefit of the CIK cell immunotherapy.
The overall incidence of AEs in the immunotherapy
group was 27.1% and there was no grade 3 or 4 AEs. In
previous studies, the reported overall incidence of AEs
varied from 3.5 to 62%, and the majority were light fever
at grade 1 or 2 in severity, which was consistent with
this study [11–14, 26, 27]. Because CIK cells are manu-
factured by the ex vivo culture of autologous PMBCs
stimulated with cytokines, they are less toxic and pro-
duce no graft-versus-host effect [28–30]. No patients in
this study had to stop or delay their CIK cell im-
munotherapy due to an AE. These results imply that
CIK cell immunotherapy is safe and well tolerated
therapeutic modality.
Fig. 3 Recurrence-free survival in selected subsets. HR, hazard ratio; RFA, radiofrequency ablation; HCC, hepatocellular carcinoma; HBV, hepatitis B
virus, HCV, hepatitis C virus, LC, liver cirrhosis; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; ALP, Alkaline phosphatase; INR, international normalized ratio; PLT, platelet; LMR, lymphocyte to monocyte ratio
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There are several limitations to our study. First, prob-
ably because of the small number of enrolled patients
and short follow-up duration, we failed to show any sur-
vival benefit of the CIK cell immunotherapy for HCC
patients. However, we showed that the adjuvant CIK cell
immunotherapy was a potent therapeutic modality for
reducing recurrence, which is the most frequent cause
of death among HCC patients. Second, this study had a
retrospective design. Therefore, there might have been
bias when selecting patients for the control group. How-
ever, in order to reduce selection bias, we used the PS
matching technique to select the control group patients.
After PS matching, there were no significant differences
between the baseline characteristics of patients in the
immunotherapy group and control group. Although
there was no significant difference, the median tumor
size of the immunotherapy group was larger than the
control group. Considering that tumor size is one of the
most important factor of HCC recurrence after curative
treatment [31–33], it might be notable that the HR for
the RFS produced by CIK cell immunotherapy in our
study was lower than that of the RCT that we previously
reported [12]. This result may refute the criticism that
the therapeutic effect of CIK cell immunotherapy was
over-estimated because patients in the immunotherapy
Table 2 Factors associated with recurrence-free survival
Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Immunotherapy (Yes vs No) 0.42 (0.22–0.80) 0.008 0.38 (0.20–0.73) 0.004
Sex (male vs female) 0.93 (0.46–1.88) 0.85 – –
Age (≥ 58 yrs vs < 58 yrs)a 0.94 (0.51–1.72) 0.84 – –
Treatment modality (Resection vs RFA) 1.73 (0.76–3.95) 0.19 – –
HCC stage (II vs I) 1.54 (0.83–2.87) 0.17 – –
Number of HCC (≥ 3 vs < 3) 2.39 (0.57–9.95) 0.23 – –
Size of HCC (≥ 2.75 cm vs < 2.75 cm)a 2.67 (1.39–5.11) 0.003 2.47 (1.25–4.90) 0.01
Cause of liver disease 0.51 – –
HBV infection 1 (reference)
HCV infection 0.78 (0.24–2.55)
Others 1.77 (0.30–10.62)
Cirrhosis (Yes vs No) 1.45 (0.77–2.73) 0.25 – –
α-fetoprotein (≥ 4 ng/mL vs < 4 ng/mL)a 1.93 (1.03–3.61) 0.04 1.12 (0.54–2.31) 0.76
PIVKA-II (≥ 20 mAU/mL vs < 20 mAU/mL)a 0.74 (0.40–1.36) 0.34 – –
Aspartate aminotransferase (≥ 30 IU/L vs < 30 IU/L)a 1.99 (1.04–3.79) 0.04 1.62 (0.81–3.24) 0.17
Alanine aminotransferase (≥ 27 IU/L vs < 27 IU/L)a 1.60 (0.86–2.97) 0.14 – –
Alkaline phosphatase (≥ 83 IU/L vs < 83 IU/L)a 1.73 (0.92–3.27) 0.09 – –
Albumin (≥ 4.2 g/dL vs < 4.2 g/dL)a 0.36 (0.19–0.68) 0.001 0.51 (0.25–1.04) 0.06
Total bilirubin (≥ 0.7 mg/dL vs < 0.7 mg/dL)a 1.40 (0.74–2.64) 0.31 – –
Prothrombin time, INR (≥ 1.09 vs < 1.09)a 1.56 (0.83–2.90) 0.17 – –
Creatinine (≥ 0.85 mg/dL vs < 0.85 mg/dL)a 0.82 (0.44–1.50) 0.52 – –
Platelet (≥ 173mm3 vs < 173mm3)a 0.69 (0.36–1.32) 0.27 – –
Lymphocyte to monocyte ratio (≥ 4.36 vs < 4.36)a 0.47 (0.25–0.89) 0.02 0.87 (0.40–1.90) 0.72
aContinuous variables are divided according to their median values
RFA radiofrequency ablation, HCC hepatocellular carcinoma, HBV hepatitis B virus, HCV hepatitis C virus, PIVKA-II protein induced by vitamin K absence-II,
INR international normalized ratio, HR hazard ratio
Table 3 Adverse events in the immunotherapy group
Adverse event Immunotherapy (n = 59)
Grade 1 or 2 Grade 3 or 4
Overall incidence 16 (27.1%) 0
Anorexia 1 (1.7%) 0
Nausea 1 (1.7%) 0
Vomiting 2 (3.4%) 0
Pruritis 2 (3.4%) 0
Chills 2 (3.4%) 0
Fatigue 4 (6.8%) 0
Pyrexia 3 (5.1%) 0
Productive cough 1 (1.7%) 0
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group had significantly smaller tumors than patients in
the control group in our previous RCT [34]. Third, we
did not identify predictors for which patients would be
responders in the immunotherapy group. We believe
that CIK cell immunotherapy should be considered as
an adjuvant treatment for patients with early stage tu-
mors. However, even if adjuvant CIK cell immunother-
apy were performed on these selected patients, 15 out of
59 patients (25.4%) of the patients would experience re-
currence. Further studies which compare pretreatment
and post-treatment factors in the responders and non-
responders are needed.
Conclusions
In conclusion, we showed that adjuvant CIK cell im-
munotherapy prolonged the RFS of HCC patients who
had undergone curative treatment in a real-world
clinical setting. All the AEs associated with the im-
munotherapy were mild to moderate in severity and
self-limiting.
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